Milestone Pharmaceuticals Inc.

1111 Dr. Frederik-Philips Boulevard, Suite 402

Montréal, Québec CA H4M 2X6




November 4, 2021


U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549


Attn:Christopher Edwards


Re:Milestone Pharmaceuticals Inc.
Registration Statement on Form S-3, as amended
File No. 333-257404


Acceleration Request

  Requested Date: Friday, November 5, 2021
  Requested Time: 4:00 P.M. Eastern Time


Ladies and Gentlemen:


In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-257404) (as amended to date, the “Registration Statement”) to become effective on Friday, November 5, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.


The Registrant hereby authorizes each of Marc Recht, Ryan Sansom and Eric Popp of Cooley LLP to make such request on its behalf.


Once the Registration Statement has been declared effective, please orally confirm that event with Eric Popp of Cooley LLP, counsel to the undersigned registrant, at (617) 937-2369.


[Signature Page Follows]





Milestone Pharmaceuticals Inc.



By: /s/ Joseph Oliveto  
  Joseph Oliveto  
  Chief Executive Officer  


cc:Amit Hasija, Milestone Pharmaceuticals Inc.
Ryan Sansom, Cooley LLP
Eric Popp, Cooley LLP